A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin aspart; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL VII
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 26 Feb 2018 Results published in the Diabetes Care.
    • 08 Dec 2017 Results evaluating short-term cost effectiveness of insulin degludec/liraglutide (IDegLira) versus basal bolus presented at the 2017 Congress of the International Diabetes Federation
    • 08 Dec 2017 Results assessing patient reported outcomes with IDegLira vs. basal bolus therapy presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top